• Users Online:1922
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2011  |  Volume : 5  |  Issue : 4  |  Page : 22-27

Bacopa monnieri - A multicentric, randomized, double-blind homoeopathic pathogenetic trial


1 Central Council for Research in Homoeopathy, New Delhi, India
2 Drug Proving Research Unit (H), Kolkata, West Bengal, India
3 Drug Proving Research Unit (H), Midnapore, West Bengal, India

Correspondence Address:
Rajpal
Central Council for Research in Homoeopathy, 61-65, Institutional Area, Janakpuri, New Delhi- 110 058
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Objective: To elicit the pathogenetic response of the drug Bacopa monnieri in homoeopathic potencies on healthy human beings. Methodology: Drug Bacopa monnieri was proved by the Central Council for Research in Homoeopathy through randomized, double-blind, placebo-controlled method. The study was conducted at two centers. The drug was proved in three potencies (6C, 30C and 200C) on 32 apparently healthy volunteers who were selected after conducting pre-trial medical examination by the medical specialists and routine laboratory investigations. In the first phase volunteers were given 56 doses (04 doses per day for 14 days) of placebo. In the next three phases 56 doses (04 doses per day for 14 days) of each potency or placebo were consumed. The symptoms generated during the trial period were noted by the volunteers and elaborated by the Proving Masters. The data obtained from both the centers was compiled at provingcum- data processing cell at CCRH headquarters after de-coding. Observations: Out of the 20 provers who were on actual drug trial, 07 manifested symptoms. Drug was able to produce symptoms in all three potencies more or less related to every part of the body. Conclusion: The pathogenetic responses elicited during the proving trial expands the scope of use of the drug Bacopa monnieri and will benefit the research scholars and clinicians. These symptoms will carry more value when verified clinically.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1117    
    Printed25    
    Emailed0    
    PDF Downloaded227    
    Comments [Add]    

Recommend this journal